Twin Star Medical is a Minnesota medical technology company pioneering the use of microporous catheters to aspirate and to infuse fluids as a local therapeutic intervention for a number of unmet medical needs. The first product to be introduced by Twin Star Medical has obtained FDA clearance and is being launched in the U.S. to treat complications from fractures.
The Department of Defense is funding clinical studies for additional FDA indications along with other product modifications for use in theater. A second product resulting from Twin Star’s research is a traumatic brain injury (TBI) catheter, for which pivotal animal studies have been completed. It is poised for human studies next year. Localized drug delivery is the next focus for the Twin Star Medical technology, with the initial clinical indications for direct delivery of cancer drugs to the tumor and surrounding tissue, across a range of tumor locations.
Product development has been financed with government grants totaling about $20 million, while commercialization funding from private equity sources focuses on sales and marketing activities.
Twin Star Medical will be presenting at the Innovation Hall of the Governor’s Job Summit at the St. Paul Crowne Plaza on October 25. The company’s dedication to medical advances is important to the state as we get Minnesota working again.